Business Context and Reporting Period
This Form 8-K was filed by Aclaris Therapeutics, Inc. on October 31, 2018. The report details a specific financing event involving the Company and its wholly owned subsidiaries, Confluence Discovery Technologies, Inc. and Aclaris Life Sciences, Inc.
Key Financial Metrics
- Debt Obligation: The Company borrowed $30.0 million under a Loan and Security Agreement with Oxford Finance LLC.
- Total Facility Size: The agreement provides for up to $65.0 million in term loans.
- Remaining Availability: $35.0 million remains available for future draws.
- Revenue and Profit: The filing text does not provide a clear value for revenue, profit, cash flow, or margins.
- Liquidity: Specific liquidity ratios or cash balances are not disclosed in this report.
Material Changes
The primary material change is the execution of a $30.0 million drawdown on October 31, 2018, pursuant to the credit facility announced on October 15, 2018. This increases the Company's direct financial obligations.
Guidance, Outlook, and Conditions
- Future Draws: The remaining $35.0 million is available for draw beginning on the closing date of the Company's acquisition of RHOFADE.
- Expiration: The availability period for the remaining funds ends on the earlier of March 31, 2019, or an event of default.
- Emerging Growth Company: The registrant is an emerging growth company and has elected not to use the extended transition period for complying with new or revised financial accounting standards.
- Documentation: The full Loan and Security Agreement is expected to be filed as an exhibit to the Annual Report on Form 10-K for the year ending December 31, 2018.
Investor Verification Checklist
- Verify the closing date of the RHOFADE acquisition to determine when the remaining $35.0 million becomes available.
- Review the full Loan and Security Agreement (to be filed in the 10-K) for interest rates, covenants, and repayment terms.
- Confirm the Company's current cash position and burn rate to assess the necessity of the remaining $35.0 million draw.
- Monitor for any events of default that could terminate the availability of the remaining funds before March 31, 2019.